Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT

Next Previous
Trial Profile

Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms Cardamon

Most Recent Events

  • 12 Dec 2023 Results testing hypothesis, in the context of consolidation or ASCT in patients enrolled in CARDAMON, whether patients with higher neoantigen load would gain most benefit from ASCT, due to immune reprogramming, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results assessing health-related quality of life and the impact of Autologous Stem Cell Transplant (ASCT) on the tolerability of maintenance, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top